Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Recruiting now

Conditions studied: Generalized Myasthenia Gravis

In brief

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

Key facts

Study ID

NCT04202341

Run by

Alexion Pharmaceuticals, Inc.

People needed

500

Starts

2019-12-02

Expected to finish

2029-10-01

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment.
• Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
• Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry.

You may not qualify if…

• Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.

Where it is running

• Clinical Trial Site — Scottsdale, Arizona, United States (enrolling)
• Clinical Trial Site — Fresno, California, United States (enrolling)
• Clinical Trial Site — Orange, California, United States (enrolling)
• Clinical Trial Site — Rancho Mirage, California, United States (enrolling)
• Clinical Trial Site — Sylmar, California, United States (enrolling)
• Clinical Trial Site — Colorado Springs, Colorado, United States (enrolling)
• Clinical Trial Site — Fort Collins, Colorado, United States (enrolling)
• Clinical Trial Site — New Haven, Connecticut, United States (enrolling)
• Clinical Trial Site — Washington D.C., District of Columbia, United States (enrolling)
• Clinical Trial Site — Clearwater, Florida, United States (enrolling)
• Clincal Trial Site — Gainesville, Florida, United States (enrolling)
• Clinical Trial Site — Jacksonville, Florida, United States (enrolling)
• Clinical Trial Site — Tampa, Florida, United States (enrolling)
• Clinical Trial Site — Augusta, Georgia, United States (enrolling)
• Clinical Trial Site — Iowa City, Iowa, United States (enrolling)
• Clinical Trial Site — Lexington, Kentucky, United States (enrolling)
• Clinical Trial Site — Boston, Massachusetts, United States (enrolling)
• Clinical Trial Site — Lansing, Michigan, United States (enrolling)
• Clinical Trial Site — Columbia, Missouri, United States (enrolling)
• Clinical Trial Site — New Hyde Park, New York, United States (enrolling)
• Clinical Trial Site — Chapel Hill, North Carolina, United States (enrolling)
• Clinical Trial Site — Charlotte, North Carolina, United States (enrolling)
• Clinical Trial Site — Durham, North Carolina, United States (enrolling)
• Clinical Trial Site — Dayton, Ohio, United States (enrolling)
• Clinical Trial Site — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.